"She is now about to go for surgery," Chang reported. "Previously, a patient like this is inoperable."
A final study found that treating estrogen receptor-positive breast cancer tumors with a combination of an experimental drug called fidarestat and Femara (the aromatase inhibitor letrozole) either delayed or eliminated tumors that had developed a resistance to hormone therapy.
Researchers at the University of Texas Health Science Center, San Antonio, found that fidarestat affects cellular metabolism of glucose, which provides energy for cells, sustaining tumor growth.
There's more on breast cancer at the U.S. National Cancer Institute.
Copyright © 2011 HealthDay. All rights reserved.